{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:17:19Z","timestamp":1785208639894,"version":"3.55.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Genetic sub-study of adults randomized to initiate TAF or TDF together with dolutegravir and emtricitabine was conducted. Outcomes were changes from week 4 to 48 in the estimated glomerular filtration rate (eGFR) and from baseline to week 48 in urine retinol-binding protein and urine \u03b22-microglobulin adjusted for urinary creatinine (uRBP\/Cr and uB2M\/Cr). Primary analyses prioritized 14 polymorphisms previously reported to be associated with tenofovir disposition or renal outcomes, and all polymorphisms in 14 selected genes. We also explored genome-wide associations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>336 participants were enrolled. Among 14 polymorphisms of primary interest, the lowest <jats:italic toggle=\"yes\">P<\/jats:italic> values for change in eGFR, uRBP\/Cr, and uB2M\/Cr were <jats:italic toggle=\"yes\">ABCC4<\/jats:italic> rs899494 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.022), <jats:italic toggle=\"yes\">ABCC10<\/jats:italic> rs2125739 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.07), and <jats:italic toggle=\"yes\">ABCC4<\/jats:italic> rs1059751 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.0088); and in genes of interest, the lowest <jats:italic toggle=\"yes\">P<\/jats:italic> values were <jats:italic toggle=\"yes\">ABCC4<\/jats:italic> rs4148481 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.0013), rs691857 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.00039), and <jats:italic toggle=\"yes\">PKD2<\/jats:italic> rs72659631 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20050.0011). However, none of these polymorphisms withstood correction for multiple testing. Genome-wide, the lowest <jats:italic toggle=\"yes\">P<\/jats:italic> values were <jats:italic toggle=\"yes\">COL27A1<\/jats:italic> rs1687402 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20053.4\u2005\u00d7\u200510<jats:sup>\u22129<\/jats:sup>), <jats:italic toggle=\"yes\">CDH4<\/jats:italic> rs66494466 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20055.6\u2005\u00d7\u200510<jats:sup>\u22128<\/jats:sup>), and <jats:italic toggle=\"yes\">ITGA4<\/jats:italic> rs3770126 (<jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u20056.1\u2005\u00d7\u200510<jats:sup>\u22127<\/jats:sup>).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Two <jats:italic toggle=\"yes\">ABCC4<\/jats:italic> polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M\/Cr, respectively, albeit in the opposite direction of previous reports. <jats:italic toggle=\"yes\">COL27A1<\/jats:italic> polymorphism was genome-wide significantly associated with change in eGFR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000491","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:28:48Z","timestamp":1682512128000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans"],"prefix":"10.1097","volume":"33","author":[{"given":"Somila","family":"Mateza","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Bradford","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso","family":"Sokhela","sequence":"additional","affiliation":[{"name":"Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomathemba C.","family":"Chandiwana","sequence":"additional","affiliation":[{"name":"Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem D.F.","family":"Venter","sequence":"additional","affiliation":[{"name":"Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Post","sequence":"additional","affiliation":[{"name":"Department of Sexual Health and HIV, King's College Hospital NHS Foundation Trust"},{"name":"Department of Infectious Diseases, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylyn D.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center"},{"name":"Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phumla","family":"Sinxadi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J Virus Erad"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity.","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV cohort study.","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/aid.2008.0202","article-title":"Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.","volume":"25","author":"Kinai","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12981-016-0113-z","article-title":"The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.","volume":"13","author":"Salome","year":"2016","journal-title":"AIDS Res Ther"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"21317","DOI":"10.7448\/IAS.20.01\/21317","article-title":"Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.","volume":"20","author":"De Waal","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","article-title":"Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.","volume":"24","author":"Rodriguez-Novoa","year":"2010","journal-title":"AIDS"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1060028016660812","article-title":"Tenofovir alafenamide.","volume":"50","author":"Gibson","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/00498250500354493","article-title":"Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.","volume":"35","author":"Mallants","year":"2005","journal-title":"Xenobiotica"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir.","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","article-title":"A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.","volume":"25","author":"Dahlin","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/infdis\/jiu107","article-title":"Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.","volume":"210","author":"Jose","year":"2014","journal-title":"J Infect Dis"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-019-0227-1","article-title":"Tenofovir-associated kidney disease in Africans: a systematic review.","volume":"16","author":"Mtisi","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3851\/IMP1832","article-title":"Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.","volume":"16","author":"Stohr","year":"2011","journal-title":"Antivir Ther"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"e89573","DOI":"10.1371\/journal.pone.0089573","article-title":"Impact of antiretroviral therapy on renal function among HIV-infected Tanzanian adults: a retrospective cohort study.","volume":"9","author":"Mpondo","year":"2014","journal-title":"PLoS One"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/tmi.12446","article-title":"Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa.","volume":"20","author":"Kamkuemah","year":"2015","journal-title":"Trop Med Int Health"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"e0184766","DOI":"10.1371\/journal.pone.0184766","article-title":"Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.","volume":"12","author":"Deckert","year":"2017","journal-title":"PLoS One"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/QAD.0b013e32834957da","article-title":"Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.","volume":"25","author":"Brennan","year":"2011","journal-title":"AIDS"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.","volume":"48","author":"Rodriguez-Novoa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/cis772","article-title":"Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.","volume":"55","author":"Nishijima","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.","volume":"154","author":"Daar","year":"2011","journal-title":"Ann Intern Med"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FPC.0000000000000156","article-title":"Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.","volume":"25","author":"Wanga","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dkaa008","article-title":"Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population.","volume":"75","author":"Neary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.","volume":"194","author":"Izzedine","year":"2006","journal-title":"J Infect Dis"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/infdis\/jir215","article-title":"Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.","volume":"204","author":"Pushpakom","year":"2011","journal-title":"J Infect Dis"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/tpj.2017.3","article-title":"Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.","volume":"18","author":"Baxi","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"e0195764","DOI":"10.1371\/journal.pone.0195764","article-title":"Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.","volume":"13","author":"Figueroa","year":"2018","journal-title":"PLoS One"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/jpet.105.084301","article-title":"Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).","volume":"314","author":"Bleasby","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine.","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"D1005","DOI":"10.1093\/nar\/gky1120","article-title":"The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019.","volume":"47","author":"Buniello","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells.","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses.","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","article-title":"Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program.","volume":"590","author":"Taliun","year":"2021","journal-title":"Nature"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"D1115","DOI":"10.1093\/nar\/gkab959","article-title":"The UCSC Genome Browser database.","volume":"50","author":"Lee","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"R40-20250808","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R41-20250808","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3851\/IMP3378","article-title":"Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?","volume":"25","author":"Post","year":"2020","journal-title":"Antivir Ther"},{"key":"R42-20250808","first-page":"434","article-title":"Renal effects of novel antiretroviral drugs.","volume":"32","author":"Milburn","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R43-20250808","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41397-021-00235-7","article-title":"ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.","volume":"21","author":"Cheli","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"R44-20250808","doi-asserted-by":"crossref","first-page":"e0147724","DOI":"10.1371\/journal.pone.0147724","article-title":"A single-nucleotide polymorphism in ABCC4 is associated with tenofovir-related Beta2-microglobulinuria in Thai patients with HIV-1 infection.","volume":"11","author":"Likanonsakul","year":"2016","journal-title":"PLoS One"},{"key":"R45-20250808","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jinf.2017.01.010","article-title":"Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.","volume":"74","author":"Hamzah","year":"2017","journal-title":"J Infect"},{"key":"R46-20250808","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2007.06.024","article-title":"Type XXVII collagen at the transition of cartilage to bone during skeletogenesis.","volume":"41","author":"Hjorten","year":"2007","journal-title":"Bone"},{"key":"R47-20250808","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ejhg.2014.107","article-title":"Mutations in COL27A1 cause steel syndrome and suggest a founder mutation effect in the Puerto Rican population.","volume":"23","author":"Gonzaga-Jauregui","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"R48-20250808","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jor.22278","article-title":"Investigation of variants within the COL27A1 and TNC genes and Achilles tendinopathy in two populations.","volume":"31","author":"Saunders","year":"2013","journal-title":"J Orthop Res"},{"key":"R49-20250808","doi-asserted-by":"crossref","first-page":"103939","DOI":"10.1016\/j.ejmg.2020.103939","article-title":"First reported case of Steel syndrome in the European population: a novel homozygous mutation in COL27A1 and review of the literature.","volume":"63","author":"Evie","year":"2020","journal-title":"Eur J Med Genet"},{"key":"R50-20250808","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome.","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"R51-20250808","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2369-13-85","article-title":"Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients.","volume":"13","author":"Campbell","year":"2012","journal-title":"BMC Nephrol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:02:03Z","timestamp":1754654523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000491","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}